Week of February 1st, 2021 | Vol. 10, Issue 5
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse

Project Bulldog
Sell-side | Pharma Services| Life sciences consulting firm
Novartis has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 vaccine. The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland.
Under the terms of the contract manufacturing agreement, Novartis plans to take bulk mRNA active ingredient from BioNTech and fill this into vials under aseptic conditions for shipment back to BioNTech for their distribution to healthcare system customers around the world.
Subject to reaching a final agreement, Novartis plans to commence production in the second quarter of 2021 at its state-of-the art aseptic manufacturing plant in Stein. Initial shipment of finished product is expected in the third quarter.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
10 transactions totaling $2,444 million
Supplies, Equipment & Services
22 transactions totaling $636 million
Healthcare IT & Managed Care
10 transactions
Healthcare Facilities & Distributors
2 transactions
Pharma & Biotech
29 transactions totaling $673 million
Supplies, Equipment & Services
32 transactions totaling $413 million
Healthcare IT & Managed Care
13 transactions totaling $39 million
Healthcare Facilities & Distributors
5 transactions totaling $3,429 million
Pharma & Biotech
24 transactions totaling $1,973 million
Supplies, Equipment & Services
15 transactions totaling $2,634 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
3 transaction totaling $323
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
January 29, 2021 - Fierce Biotech
Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies. As with its earlier funds, Arch will use the money to place a wide range of bets, handing out $50,000 when appropriate but also dialing its investment up to $250 million to support grand plans such as its effort to transform biopharmaceutical manufacturing through Resilience.

January 27, 2021 - Fierce Pharma
Pfizer and Moderna have agreed to deliver another 200 million COVID-19 vaccine doses to the U.S., bringing the total on tap to 600 million, or enough to vaccinate 300 million people. President Joe Biden announced the pending deals on Tuesday, noting the extra doses would be delivered this summer.

January 29, 2021 - Fierce Pharna
Lilly's first COVID-19 antibody, bamlanivimab, generated $871 million in fourth-quarter revenues, driving the drugmaker to a 22% revenue increase for the period. Excluding the COVID-19 antibody, Lilly’s revenues grew 7%.

January 29, 2021 - Fierce Pharma
The vaccine, the result of AZ's collaboration with Oxford University, is conditionally approved across Europe in people ages 18 and older. A broad rollout in EU member countries will follow, but in recent days, a reduction in first-quarter supply has dominated headlines. 
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.